CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AstraZeneca Pharmaceuticals LP v. Aurobindo Pharma Limited Inc.

1:08-cv-00359

Overview

Case Number 1:08-cv-00359
Filing Date 2008-06-24
Status Terminated
Termination Date 2010-07-13
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Defendant

Parties

Movant

AstraZeneca Pharmaceuticals LP NPE (Individual / Inventor)

Represented By

4 Attorneys Listed

Mary K. Ferguson

Email: Mary.Ferguson@finnegan.com

Mary W. Bourke

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4320

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

John D. Livingstone

Email: john.livingstone@finnegan.com

Andrew T. Berry

McCarter & English LLP

Tel: +1 (973) 622-4444

Four Gateway Center, 100 Mulberry Street

Defendant

Aurobindo Pharma Limited Inc. NPE (University / Research)

Represented By

7 Attorneys Listed

Jeffrey S. Ward

Email: jward@merchantgould.com

Stephen B. Brauerman

Bayard, P.A.

Tel: +1 (302) 429-4232
Fax: +1 (302) 658-6395

Bayard, P.A., 222 Delaware Avenue, Suite 900

Richard D. Kirk

Bayard, P.A.

Tel: +1 (302) 429-4208
Fax: +1 (302) 658-6395

Bayard, P.A., 222 Delaware Avenue, Suite 900

Thomas P. Heneghan

UNDELIVERABLE EMAIL 3/22/12

Edward J. Pardon

Email: epardon@merchantgould.com

Shane A. Brunner

Email: sbrunner@merchantgould.com

Arnold B. Calmann

Saiber LLC

Tel: +1 (973) 622-3333

Saiber LLC, One Gateway Center

Aurobindo Pharma USA Inc. Operating Company

Represented By

4 Attorneys Listed

Stephen B. Brauerman

Bayard, P.A.

Tel: +1 (302) 429-4232
Fax: +1 (302) 658-6395

Bayard, P.A., 222 Delaware Avenue, Suite 900

Richard D. Kirk

Bayard, P.A.

Tel: +1 (302) 429-4208
Fax: +1 (302) 658-6395

Bayard, P.A., 222 Delaware Avenue, Suite 900

Shane A. Brunner

Email: sbrunner@merchantgould.com

Arnold B. Calmann

Saiber LLC

Tel: +1 (973) 622-3333

Saiber LLC, One Gateway Center

Plaintiff

Shionogi Seiyaku Kabushiki Kaisha Operating Company

Represented By

2 Attorneys Listed

Mary W. Bourke

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4320

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

Andrew T. Berry

McCarter & English LLP

Tel: +1 (973) 622-4444

Four Gateway Center, 100 Mulberry Street

IPR Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

Mary W. Bourke

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4320

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

Andrew T. Berry

McCarter & English LLP

Tel: +1 (973) 622-4444

Four Gateway Center, 100 Mulberry Street

AstraZeneca UK Limited NPE (University / Research)

Represented By

2 Attorneys Listed

Mary W. Bourke

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4320

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

Andrew T. Berry

McCarter & English LLP

Tel: +1 (973) 622-4444

Four Gateway Center, 100 Mulberry Street

Counter Claimant

AUROBINDO PHARMA LIMITED, INC. NPE (University / Research)

Represented By

1 Attorneys Listed

Arnold B. Calmann

Saiber LLC

Tel: +1 (973) 622-3333

Saiber LLC, One Gateway Center

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

No Co-Pending Disputes Detected in Current Index

There are no other active filings for this patent family across our indexed PTAB, U.S. Court, UPC, or EPO databases.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
USRE37314
Pyrimidine derivatives
Filed: 1998-08-27
Issued: 2001-08-07
Expired (Term Ended)
Expires: 2016-01-08

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

47

Dispositive

25

Granted

2

Denied

2

Pending / Review

42

Motions by Category

Motion to Dismiss 15 Procedural / Extension Motion 5 Motion to Stay Pending IPR / Reexam 2 Motion to Stay 1 Motion to Dismiss (FRCP 12(b)(6)) 1 Claim Construction / Markman Filing 12 Motion to Strike / Sanctions 4 Motion for Summary Judgment (Rule 56) 7

Key Dispositive Motions & Rulings

Motion to Dismiss Granted
ORDER Granting Plaintiffs' Motion For Leave To File A Sur-Reply (see 546 in 08-md1949-JJF); GRANTING Defendants' Motion To Dismiss AstraZeneca Pharmaceuticals, ...
Entry #255 • 2010-06-29 Document →
Motion to Dismiss Pending / Under Review
REDACTED VERSION of (217 in 1:07-cv-00806-JJF, 194 in 1:08-cv-00359-JJF, 330 in 1:07-cv-00810-JJF, 210 in 1:07-cv-00808-JJF, 249 in 1:07-cv-00809-JJF, 262 in 1:...
Entry #216 • 2010-03-04 Document →
Motion to Dismiss Pending / Under Review
REDACTED VERSION of (261 in 1:07-cv-00811-JJF, 193 in 1:08-cv-00359-JJF, 232 in 1:07-cv-00807-JJF, 197 in 1:08-cv-00426-JJF, 248 in 1:07-cv-00809-JJF, 443 in 1:...
Entry #215 • 2010-03-02 Document →
Motion to Dismiss Granted
ORDER Granting 481 STIPULATION TO EXTEND TIME from February 26, 2010 to March 1, 2010 regarding Motion to Dismiss, filed by Aurobindo Pharma Ltd., (Reset Briefi...
Entry #213 • 2010-03-01 Document →
Motion to Dismiss Pending / Under Review
SEALED MEMORANDUM in Opposition re Motion to Dismiss Astrazeneca Pharmaceuticals Lp for Lack of Standing, filed by AstraZeneca Pharmaceuticals LP, AstraZeneca U...
Entry #193 • 2010-02-16 Document →
Motion to Dismiss Pending / Under Review
SEALED DECLARATION re 193 Memorandum in Opposition re Motion to Dismiss Astrazeneca Pharmaceuticals Lp for Lack of Standing, by AstraZeneca Pharmaceuticals LP, ...
Entry #194 • 2010-02-16 Document →

Docket Entries

(290 total)
Pleading / Complaint

COMPLAINT against AUROBINDO PHARMA LIMITED, INC., AUROBINDO PHARMA USA INC. ( Filing fee $ 350 receipt number 1783945.), filed by ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS, INC., SHIONOGI SEIYAKU KABUSHIKI KAISHA.(Attachments: # 1 RULE 7.1)(jh) [Transferred from New Jersey on 6/24/2008.] (Entered: 12/20/2007)

Entry #1 • 2007-12-18
1

Summons Issued as to AUROBINDO PHARMA LIMITED, INC., AUROBINDO PHARMA USA INC..Days Due - 20. MAILED TO ATTORNEY (jh) [Transferred from New Jersey on 6/24/2008.] (Entered: 12/20/2007)

Entry #2 • 2007-12-20
1

AO120 Patent/Trademark Form filed. (jh) [Transferred from New Jersey on 6/24/2008.] (Entered: 12/20/2007)

Entry #3 • 2007-12-20
1
Pleading / Complaint

Defendant Aurobindo Pharma Limited's ANSWER to Complaint, COUNTERCLAIM against ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS, INC., SHIONOGI SEIYAKU KABUSHIKI KAISHA by AUROBINDO PHARMA LIMITED, INC.. (Attachments: # 1 Certificate of Service)(CALMANN, ARNOLD) [Transferred from New Jersey on 6/24/2008.] (Entered: 01/31/2008)

Entry #4 • 2008-01-31
1

Corporate Disclosure Statement by AUROBINDO PHARMA LIMITED, INC., AUROBINDO PHARMA USA INC. identifying Aurobindo Pharma Limited as Corporate Parent.. (CALMANN, ARNOLD) [Transferred from New Jersey on 6/24/2008.] (Entered: 01/31/2008)

Entry #5 • 2008-01-31
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc